Top Markets
#1 Siren Siren +45.30%
#2 Helium Helium +15.28%
#3 Cryptopia Cryptopia +9.12%
#4 Verus Coin Verus Coin +6.66%
#5 Useless Coin Useless Coin +5.99%
#6 OpenGradient OpenGradient +4.98%
#7 o1.exchange o1.exchange +4.73%
#8 Across Protocol Across Protocol +4.69%
#9 PondCoin PondCoin +4.47%
#10 Mubarak Mubarak +4.45%
Coin of the day
Siren Siren
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Intercept Pharmaceuticals, Inc. Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals, Inc.

ICPT
Rangering i aksjer #12026
Intercept Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the... Intercept Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the advancement and market launch of therapies designed to treat progressive, non-viral liver conditions. Its operational reach spans the United States, Europe, and Canada. The company currently markets Ocaliva, a medication functioning as a farnesoid X receptor (FXR) agonist. This drug is approved for the treatment of primary biliary cholangitis (PBC) in adults, specifically when administered alongside ursodeoxycholic acid. Beyond its existing approved indications, Intercept is actively investigating Ocaliva's potential for additional uses, notably including nonalcoholic steatohepatitis (NASH). Concurrently, it is progressing other drug candidates through various clinical and preclinical stages of development. In a collaborative effort, the company holds a licensing agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. Intercept distributes its products through a dual approach, utilizing both its proprietary commercial organization and a network of external third-party distributors. The company was founded in 2002 and is headquartered in New York, New York.
Aksjekurs
$19.00
Sist synkronisert: 2023-11-14
Markedsverdi
$629.64M
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Intercept Pharmaceuticals, Inc. (ICPT)

Kategori

Healthcare
P/E-forhold for Intercept Pharmaceuticals, Inc. (ICPT)
P/E-forhold per 2026 TTM: 0
Ifølge Intercept Pharmaceuticals, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Intercept Pharmaceuticals, Inc. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.